Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Shandong Xinhua Pharmaceutical Company Limited Class H ( (HK:0719) ) has provided an announcement.
Shandong Xinhua Pharmaceutical Company Limited has announced the receipt of the Drug Registration Certificate for its Memantine hydrochloride oral solution from the National Medical Products Administration. This approval marks a significant milestone for the company, enabling it to proceed with the production and sale of the drug, potentially enhancing its market position in the pharmaceutical industry.
More about Shandong Xinhua Pharmaceutical Company Limited Class H
Shandong Xinhua Pharmaceutical Company Limited is a pharmaceutical company based in China, specializing in the production of chemical drugs. The company focuses on the development and manufacturing of prescription medications, contributing to the healthcare industry with a range of pharmaceutical products.
YTD Price Performance: -6.37%
Average Trading Volume: 2,139,988
Technical Sentiment Signal: Hold
Current Market Cap: HK$8.49B
Find detailed analytics on 0719 stock on TipRanks’ Stock Analysis page.